Wockhardt Ltd logo

Wockhardt Ltd

WOCKPHARMA NSE

Key Fundamentals

SmallcapPharmaceuticalsHealthcare
Market Cap
₹30,597 Cr
Volatility
Moderate
P/E Ratio
73.89
EBITDA
₹763 Cr
Return on Equity
3.77%
Debt to Equity
0.45
Book Value
₹304.03
52W High
₹2,422.3
52W Low
₹1,086.7

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Wockhardt Ltd insights

38 extracted metrics + investor summaries across FY15–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Weaknesses

4
  • Stock is trading at 6.25 times its book value
  • The company has delivered a poor sales growth of 4.49% over past five years.
  • Company has a low return on equity of -1.43% over last 3 years.
  • Promoter holding has decreased over last 3 years: -9.31%

Growth Rate

Revenue Growth
13.34% ↗
Net Income Growth
-449.12% ↘
Cash Flow Change
1872.73% ↗
ROE
-409.02% ↘
ROCE
64.96% ↗
EBITDA Margin (Avg.)
47.97% ↗

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 5d ago
AI opinion · based on fundamentals
Risk high

Wockhardt Ltd (market cap ₹30,313 Cr) is in the midst of a turnaround, swinging from years of losses to profitability in FY26 with PBT of ₹238 Cr and EBITDA growth of 51%. The stock trades at a PE of 72.5x and 6.08x book value, reflecting high expectations from its novel antibiotic pipeline (Zaynich, Miqnaf, Emrok) against a backdrop of historically weak sales growth (5-year CAGR of just 4%) and declining promoter holding.

Bull Case 8
  • US FDA approved novel antibiotic Zaynich (cefepime/zidebactam) in May 2026 with management-projected peak sales potential of $1.5-2 billion in a $7-9 billion addressable market
  • FY26 full-year EBITDA grew 51% to ₹630 Cr with revenue reaching ₹3,373 Cr, signalling a decisive operational turnaround
  • Q1 FY27 sales surged 26% YoY to ₹929 Cr from ₹738 Cr, with net profit of ₹107 Cr versus a net loss of ₹108 Cr a year ago — a 199% YoY swing
  • Specialty business grew 23% in FY26 with Emrok showing approximately 50% growth and biotech business up 27%, diversifying revenue away from generics
  • Miqnaf (nafithromycin) — India's first indigenously discovered antibiotic — received CDSCO approval in January 2025 and Lancet Regional Health published its Phase 3 data in September 2025, validating clinical differentiation
  • Stock CAGR of 97% over 3 years reflects market re-rating of the pipeline story, with TTM sales growth accelerating to 18%
  • Promoter pledging has declined from 21.3% in September 2025 to 14.7% in June 2026, indicating improving promoter financial health
  • TTM compounded profit growth of 983% shows the scale of earnings recovery from a very depressed base
Bear Case 8
  • PE ratio of 72.5x is expensive for a company with 5-year compounded sales growth of only 4% and 10-year sales CAGR of negative 3%
  • 3-year average ROE is negative at -1.4%, and even the latest year ROE of 6% is well below pharma sector averages
  • Promoter holding has declined by 9.31% over the last 3 years, and 14.7% of promoter shares remain pledged as of June 2026
  • Trading at 6.08x book value despite historically poor return ratios, leaving limited margin of safety if pipeline commercialisation disappoints
  • 5-year compounded profit CAGR is negative 19%, indicating that current profitability is a recent reversal rather than a sustained trend
  • Zero dividend yield — the company has not returned capital to shareholders while undergoing its turnaround
  • Zaynich peak sales projections of $1.5-2 billion are management estimates in a space where antibiotic commercial launches have historically underperformed expectations
  • Q1 FY27 net profit declined 35% QoQ from ₹164 Cr to ₹107 Cr, showing potential quarterly volatility in the early stages of the turnaround

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 6h ago
Positives 1
  • Return to profitability in Q1FY27 Aug 11

    Wockhardt posted ₹106 crore consolidated net profit in Q1FY27 versus a loss of ₹90 crore YoY. Revenue surged 25.9% to ₹929 crore, with standalone profit at ₹107 crore on ₹561 crore revenue.

Neutral 1
  • AGM time revised to morning Aug 5

    Wockhardt revised its 27th AGM timing from 3:30 p.m. to 10:30 a.m. IST on August 10, 2026, along with updated related party transaction disclosures.

TL;DR: Wockhardt has swung back to profitability with strong revenue growth of 25.9% YoY in Q1FY27, signalling improved operational execution. There are no notable headwinds in recent news flow. The trend is clearly improving, and sustained top-line momentum could further strengthen investor confidence in coming quarters.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
644
753
701
700
739
809
721
743
738
782
888
965
929
Expenses
628
681
664
759
648
699
593
679
666
604
711
740
737
Operating Profit
16
72
37
-59
91
110
128
64
72
178
177
225
192
OPM %
2.5%
10%
5%
-8%
12%
14%
18%
9%
10%
23%
20%
23%
21%
Other Income
0
24
8
10
30
9
8
15
-77
21
15
67
31
Interest
79
76
77
73
73
73
60
48
48
55
60
50
52
Depreciation
55
55
55
58
54
55
55
53
56
53
65
53
55
PBT
-118
-35
-87
-180
-6
-9
21
-22
-109
91
67
189
116
Tax %
15%
109%
-1%
-2%
167%
78%
5%
105%
-1%
10%
9%
13%
8%
Net Profit
-136
-73
-86
-177
-16
-16
20
-45
-108
82
61
164
107
EPS in Rs
-9.3
-5.34
-5.76
-11.02
-0.91
-1.43
0.86
-1.54
-5.54
4.8
3.63
10.22
6.52
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
4,482
4,453
4,015
3,937
3,566
2,844
2,708
3,230
2,651
2,798
3,012
3,373
3,564
Expenses
3,772
3,959
4,002
3,935
3,604
2,725
2,771
2,932
2,549
2,707
2,619
2,721
2,792
Operating Profit
709
494
13
2
-38
119
-63
298
102
91
393
652
772
OPM %
16%
11%
0.3%
0.1%
-1.1%
4.2%
-2.3%
9%
3.9%
3.2%
13%
19%
22%
Other Income
67
66
114
-238
116
133
975
-163
-173
17
62
26
134
Interest
55
129
225
255
265
276
249
299
302
305
254
213
217
Depreciation
145
142
149
150
164
224
246
247
251
223
217
227
226
PBT
575
289
-247
-641
-351
-247
417
-411
-624
-420
-16
238
463
Tax %
28%
13%
-9%
4%
-38%
-82%
-65%
-32%
0%
12%
256%
16%
—
Net Profit
413
252
-226
-667
-217
-43
688
-279
-621
-472
-57
199
414
EPS in Rs
28.3
17.45
-13.62
-42.3
-13.52
-4.81
47.64
-16.94
-38.8
-30.18
-2.89
13.11
25.17
Div. Payout %
54%
0%
-56%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
55
55
55
55
55
55
55
72
72
77
81
81
Reserves
3,362
3,720
3,281
2,797
2,619
2,616
3,321
3,777
3,282
3,282
4,272
4,859
Borrowings
2,309
2,677
4,160
3,748
3,375
3,582
2,674
2,198
2,184
2,356
2,021
2,233
Other Liabilities
1,213
1,622
1,486
1,528
1,764
1,894
1,696
2,168
2,113
1,899
1,726
1,405
Total Liabilities
6,939
8,074
8,982
8,128
7,813
8,148
7,746
8,215
7,651
7,614
8,100
8,578
Fixed Assets
2,123
2,809
2,773
2,888
3,058
3,502
3,343
3,462
3,042
2,881
2,736
2,791
CWIP
1,007
1,036
1,244
1,433
1,445
1,585
1,379
1,342
1,539
1,722
2,033
2,379
Investments
341
0
563
214
0
0
0
0
0
0
422
412
Other Assets
3,468
4,228
4,403
3,593
3,309
3,060
3,024
3,411
3,070
3,011
2,909
2,996
Total Assets
6,939
8,074
8,982
8,128
7,813
8,148
7,746
8,215
7,651
7,614
8,100
8,578
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
355
-42
-269
68
183
649
-287
413
153
219
-22
390
Investing
-222
-105
-684
635
93
-147
1,471
-204
-118
-138
-780
-231
Financing
-76
193
1,254
-769
-776
-680
-1,171
-71
-315
334
409
-54
Net Cash Flow
57
46
301
-66
-500
-178
13
138
-280
415
-393
105
Free Cash Flow
-76
-105
-678
-238
127
486
-452
202
23
69
-377
76
CFO/OP
73
-8
-1,887
4,697
-583
560
270
171
161
274
-13
63
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
60
91
94
89
130
159
124
104
110
81
80
64
Inventory Days
250
249
243
174
183
209
256
222
216
201
234
286
Days Payable
136
144
117
122
187
272
223
265
285
240
191
182
Cash Conversion Cycle
175
196
220
141
126
97
157
60
41
41
123
168
Working Capital Days
14
52
36
-56
-51
-171
-133
-116
-186
-163
-23
35
ROCE %
10%
7%
-1%
-1%
-1%
-1%
-3%
1%
0%
-1%
4%
8%

Shareholding Pattern

As of Jun 2026
Promoters 49.08%
Public 27.31%
DIIs 9.24%
FIIs 7.22%
Others 7.13%
Government 0.02%
Total 100.00%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Nov 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
72.12%
69.68%
68.04%
67.13%
67.13%
65.75%
63.83%
60.36%
59.31%
58.40%
55.14%
54.93%
51.60%
51.99%
51.99%
49.09%
49.09%
49.09%
49.09%
49.08%
49.08%
49.08%
49.08%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
3.02%
0.00%
5.49%
5.93%
6.70%
6.62%
6.54%
6.81%
7.29%
7.10%
6.99%
7.09%
7.22%
DIIs
0.02%
0.02%
0.02%
0.03%
0.03%
0.03%
0.03%
0.23%
0.22%
0.19%
0.22%
0.10%
4.83%
4.45%
5.09%
9.88%
9.82%
10.59%
11.01%
11.01%
10.55%
10.96%
9.24%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.01%
0.01%
0.02%
0.02%
0.02%
0.02%
0.02%
0.02%
0.02%
0.04%
0.02%
Public
21.41%
23.02%
25.24%
25.99%
24.56%
25.97%
27.42%
30.26%
31.45%
32.19%
32.89%
32.94%
29.94%
30.18%
29.02%
27.45%
27.49%
26.69%
26.05%
26.10%
26.52%
25.89%
27.31%
Others
6.46%
7.27%
6.69%
6.85%
8.28%
8.26%
8.72%
9.15%
9.02%
9.21%
8.72%
12.03%
8.13%
7.43%
7.19%
6.95%
7.04%
6.80%
6.55%
6.69%
6.84%
6.94%
7.13%
No. of Shareholders
0
0
1,25,128
1,44,845
1,61,625
1,65,270
1,66,122
1,80,170
1,80,630
1,78,915
1,72,989
1,61,813
1,46,376
1,40,391
1,38,142
1,43,876
1,42,710
1,41,799
1,46,918
1,37,946
1,42,274
1,39,016
1,66,518

Documents

Frequently Asked Questions about Wockhardt Ltd

What does Wockhardt Ltd do?
Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments). [1]
Where is Wockhardt Ltd (WOCKPHARMA) listed?
Wockhardt Ltd is listed on the Indian stock exchanges. It is listed on NSE: WOCKPHARMA and BSE: 532300. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Wockhardt Ltd belong to?
Wockhardt Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Wockhardt Ltd?
Wockhardt Ltd has a market capitalisation of approximately ₹30597.28 Cr. Based on this, it is classified as a Large Cap stock.
What is the PE ratio of Wockhardt Ltd?
The Price-to-Earnings (PE) ratio of Wockhardt Ltd is 73.89. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Wockhardt Ltd?
Over the past 52 weeks, Wockhardt Ltd has traded between a low of ₹1,086.7 and a high of ₹2,422.3. This range helps investors understand the stock's price volatility and recent trading levels.
What is the Return on Equity (ROE) of Wockhardt Ltd?
Wockhardt Ltd has a Return on Equity (ROE) of 3.77%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Wockhardt Ltd on Tapetide?
On Tapetide, you can view Wockhardt Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments). [1]

Website wockhardt.com
CEO Dr. Habil Fakhruddin Khorakiwala
Employees 2,296
Listed 2000-02-23
Face Value ₹ 5
Issued Size 16,24,92,169

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List